Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -19.90 | — | — | — | 18.19 | — | — | — | — | 21.98 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 20.62 | 40.35 | 30.63 | 35.78 | 6.36 | — | 8.21 | 15.90 | 4.76 | 3.12 | 4.34 | 8.54 | 132.76 |
| — | — | +273.3% | +125.0% | +33.6% | — | +89.0% | +86.1% | -96.4% | -98.9% | -97.0% | -50.6% | +421.9% | |
| P/B Ratio | 9.19 | 9.86 | 7.65 | 7.64 | 10.17 | 7.27 | 146.99 | 31.42 | 13.97 | — | — | — | — |
| — | +35.6% | -94.8% | -75.7% | -27.2% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | 1.30 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | 18.45 | — | — | — | — | 22.55 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 20.19 | — | — | — | — | 28.62 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Wave Life Sciences Ltd.'s operating margin was -740.7% in Q3 2025, down 134.2 pp QoQ and down 1573.4 pp YoY. This marks the 5th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -465.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 74.8% | 76.4% | 100.0% | 100.0% | 100.0% | 100.0% | 92.5% | 35.7% | -50.7% | -139.6% | -2408.3% |
| — | 0.0% | -25.2% | -23.6% | +8.1% | +180.1% | +297.2% | +171.6% | +103.8% | +100.4% | +99.4% | +90.5% | -77.1% | |
| Operating Margin | -101.9% | -740.7% | -606.5% | -542.8% | 27.4% | 832.7% | -177.7% | -274.8% | -64.3% | 9.0% | -106.2% | -234.2% | -3516.0% |
| — | -189.0% | -241.3% | -97.5% | +142.7% | +9121.0% | -67.4% | -17.3% | +98.2% | +100.1% | +99.1% | +89.2% | -71.9% | |
| Net Margin | -89.6% | -707.8% | -580.2% | -510.9% | 34.9% | 804.8% | -167.2% | -251.7% | -55.9% | 14.7% | -95.5% | -212.0% | -3527.8% |
| — | -187.9% | -247.0% | -103.0% | +162.4% | +5361.9% | -75.1% | -18.7% | +98.4% | +100.1% | +99.1% | +90.2% | -79.0% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -77.9% | -40.8% | -32.4% | -24.6% | 16.3% | -80.3% | -221.1% | -97.1% | -41.0% | — | — | — | — |
| — | +49.1% | +85.3% | +74.7% | +139.7% | — | — | — | — | — | — | — | — | |
| ROA | -30.9% | -21.8% | -18.7% | -14.6% | 8.2% | -21.8% | -14.8% | -12.4% | -6.8% | 3.4% | -8.5% | -13.3% | -26.7% |
| — | -0.2% | -25.9% | -18.3% | +220.2% | -745.5% | -74.7% | +6.6% | +74.3% | +117.1% | +60.9% | +34.4% | -56.2% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 32.0% YoY to 2.51x, strengthening the short-term liquidity position. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.16 | 0.16 | 0.14 | 0.12 | 0.18 | 6.57 | 1.20 | 0.81 | — | — | — | — |
| — | -12.6% | -97.6% | -88.6% | -85.0% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | 1.01 | — | — | — | — | 5.97 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.89 | 2.51 | 2.56 | 2.95 | 2.89 | 1.90 | 0.99 | 1.19 | 1.26 | 1.59 | 1.32 | 1.66 | 1.38 |
| — | +32.0% | +157.3% | +148.9% | +128.7% | +19.8% | -24.5% | -28.4% | -8.4% | -22.5% | -47.3% | -22.1% | -45.6% | |
| Quick Ratio | 2.89 | 2.51 | 2.56 | 2.95 | 2.89 | 1.90 | 0.99 | 1.19 | 1.26 | 1.59 | 1.32 | 1.66 | 1.38 |
| — | +32.0% | +157.3% | +148.9% | +128.7% | +19.8% | -24.5% | -28.4% | -8.4% | -22.5% | -47.3% | -22.1% | -45.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonWave Life Sciences Ltd.'s current P/E is -19.9x. The average P/E over the last 1 quarters is 18.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Wave Life Sciences Ltd.'s current operating margin is -101.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Wave Life Sciences Ltd.'s business trajectory between earnings reports.